XBI holdingswhat does SPDR S&P Biotech ETF hold?
Mayores posiciones según el reporte SEC Formulario N-PORT más reciente del fondo (reportado trimestralmente, presentado con rezago). Los porcentajes son sobre los activos netos. SEC Formulario N-PORT · al 2026-03-31
Las 50 mayores posicionesPeso de las 10 mayores posiciones: 20.4%al 2026-03-31
| # | Posición | Peso | Valor |
|---|---|---|---|
| 1 | State Street Global AdvisorsGVMXX | 8.01% | $595.46M |
| 2 | Apellis Pharmaceuticals Inc | 1.83% | $136.40M |
| 3 | Alkermes PLC | 1.45% | $107.88M |
| 4 | Madrigal Pharmaceuticals IncMDGL | 1.38% | $102.81M |
| 5 | TG Therapeutics IncTGTX | 1.35% | $100.33M |
| 6 | Insmed IncINSM | 1.34% | $99.39M |
| 7 | Scholar Rock Holding CorpSRRK | 1.30% | $96.45M |
| 8 | Apogee Therapeutics IncAPGE | 1.28% | $95.48M |
| 9 | Protagonist Therapeutics IncPTGX | 1.24% | $92.55M |
| 10 | Summit Therapeutics IncSMMT | 1.24% | $92.27M |
| 11 | United Therapeutics CorpUTHR | 1.24% | $92.23M |
| 12 | Praxis Precision Medicines IncPRAX | 1.24% | $91.91M |
| 13 | Arrowhead Pharmaceuticals IncARWR | 1.23% | $91.43M |
| 14 | Cogent Biosciences IncCOGT | 1.22% | $90.38M |
| 15 | Bridgebio Pharma IncBBIO | 1.19% | $88.13M |
| 16 | PTC Therapeutics IncPTCT | 1.18% | $87.89M |
| 17 | Cytokinetics IncCYTK | 1.18% | $87.76M |
| 18 | Alnylam Pharmaceuticals IncALNY | 1.18% | $87.48M |
| 19 | Exelixis IncEXEL | 1.17% | $87.03M |
| 20 | Nuvalent Inc | 1.17% | $86.75M |
| 21 | Kymera Therapeutics Inc | 1.16% | $86.56M |
| 22 | CG oncology Inc | 1.16% | $86.42M |
| 23 | Natera Inc | 1.16% | $86.18M |
| 24 | Neurocrine Biosciences Inc | 1.16% | $86.16M |
| 25 | Twist Bioscience Corp | 1.16% | $85.92M |
| 26 | Krystal Biotech Inc | 1.15% | $85.83M |
| 27 | Vaxcyte Inc | 1.15% | $85.58M |
| 28 | Mirum Pharmaceuticals Inc | 1.15% | $85.31M |
| 29 | Amicus Therapeutics Inc | 1.15% | $85.25M |
| 30 | Ionis Pharmaceuticals Inc | 1.14% | $85.07M |
| 31 | Travere Therapeutics Inc | 1.14% | $85.07M |
| 32 | Arcellx Inc | 1.14% | $85.06M |
| 33 | Regeneron Pharmaceuticals Inc | 1.14% | $84.53M |
| 34 | Incyte Corp | 1.13% | $84.24M |
| 35 | Celcuity Inc | 1.12% | $83.54M |
| 36 | Revolution Medicines Inc | 1.11% | $82.74M |
| 37 | Halozyme Therapeutics Inc | 1.11% | $82.37M |
| 38 | Rhythm Pharmaceuticals Inc | 1.10% | $81.85M |
| 39 | Biogen Inc | 1.10% | $81.56M |
| 40 | Arcutis Biotherapeutics Inc | 1.09% | $80.99M |
| 41 | AbbVie Inc | 1.09% | $80.93M |
| 42 | Gilead Sciences Inc | 1.09% | $80.87M |
| 43 | CRISPR Therapeutics AG | 1.09% | $80.72M |
| 44 | BioMarin Pharmaceutical Inc | 1.07% | $79.35M |
| 45 | Roivant Sciences Ltd | 1.07% | $79.34M |
| 46 | Amgen Inc | 1.06% | $79.01M |
| 47 | ImmunityBio Inc | 1.06% | $78.57M |
| 48 | Beam Therapeutics Inc | 1.04% | $77.41M |
| 49 | Viking Therapeutics Inc | 1.04% | $77.09M |
| 50 | Vera Therapeutics Inc | 1.03% | $76.92M |
Posiciones de ETF
SEC Form N-PORT data · Reported quarterly, filed with a lag · For reference only · Not investment advice